Literature DB >> 3541054

Pharmacologic modelling of Alzheimer's disease.

T Sunderland, P N Tariot, H Weingartner, D L Murphy, P A Newhouse, E A Mueller, R M Cohen.   

Abstract

Evidence pointing to the central role of the cholinergic system in normal human memory function and disorders such as Alzheimer's disease has grown tremendously in recent years. Anticholinergic and non-cholinergic agents have been found to create transient memory impairments in young adults which mimic the changes associated with normal aging or amnesia. The rationale for using scopolamine, a centrally active anticholinergic agent, as a pharmacologic probe of memory function is reviewed using data from studies in animals and humans. The cognitive functioning of normal elderly controls given scopolamine is compared to the baseline functioning of patients with Alzheimer's disease, followed by a discussion of the use of scopolamine as a modelling agent for dementia.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3541054     DOI: 10.1016/0278-5846(86)90030-8

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  30 in total

1.  Probing peripheral and central cholinergic system responses.

Authors:  C A Naranjo; J Fourie; N Herrmann; K L Lanctôt; C Birt; K K Yau
Journal:  J Psychiatry Neurosci       Date:  2000-09       Impact factor: 6.186

2.  Cholinergic modulation of hippocampal activity during episodic memory encoding in postmenopausal women: a pilot study.

Authors:  Julie A Dumas; Brenna C McDonald; Andrew J Saykin; Thomas W McAllister; Mary L Hynes; John D West; Paul A Newhouse
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

3.  RU 41,656 does not reverse the scopolamine-induced cognitive deficit in healthy volunteers.

Authors:  A Patat; M J Klein; A Surjus; M Hucher; J Granier
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  Drug-induced cognition disorders in the elderly: incidence, prevention and management.

Authors:  S L Gray; K V Lai; E B Larson
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

5.  TRH attenuates scopolamine-induced memory impairment in humans.

Authors:  S E Molchan; A M Mellow; B A Lawlor; H J Weingartner; R M Cohen; M R Cohen; T Sunderland
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Galantamine reverses scopolamine-induced behavioral alterations in Dugesia tigrina.

Authors:  Latha Ramakrishnan; Christina Amatya; Cassie J DeSaer; Zachary Dalhoff; Michael R Eggerichs
Journal:  Invert Neurosci       Date:  2014-01-09

Review 7.  Animal models in the drug discovery pipeline for Alzheimer's disease.

Authors:  Debby Van Dam; Peter Paul De Deyn
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

8.  The prominent role of stimulus processing: cholinergic function and dysfunction in cognition.

Authors:  Maura L Furey
Journal:  Curr Opin Neurol       Date:  2011-08       Impact factor: 5.710

Review 9.  Estrogen-cholinergic interactions: Implications for cognitive aging.

Authors:  Paul Newhouse; Julie Dumas
Journal:  Horm Behav       Date:  2015-07-14       Impact factor: 3.587

10.  MEG resting state functional connectivity in Parkinson's disease related dementia.

Authors:  J L W Bosboom; D Stoffers; E Ch Wolters; C J Stam; H W Berendse
Journal:  J Neural Transm (Vienna)       Date:  2008-11-04       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.